Scholar Rock Presents New Data From SRK-181 Phase 1 DRAGON Trial At The ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Scholar Rock (NASDAQ:SRRK) will present new data from its Phase 1 DRAGON trial of SRK-181 in combination with pembrolizumab for advanced solid tumors at the ASCO Annual Meeting. The presentation will take place on June 3rd, followed by a webcast on June 4th.
May 28, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scholar Rock will present updated safety and efficacy results from its Phase 1 DRAGON trial of SRK-181 at the ASCO Annual Meeting. This could generate positive investor sentiment and impact the stock price.
The presentation of new data at a major conference like ASCO can significantly influence investor sentiment. Positive safety and efficacy results could lead to a short-term increase in SRRK's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100